It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Idiopathic hypersomnia (IH), characterized by an excessive day-time sleepiness, a prolonged total sleep time on 24 h and/or a reduced sleep latency, affects 1 in 2000 individuals from the general population. However, IH remains underdiagnosed and inaccurately treated despite colossal social, professional and personal impacts. The pathogenesis of IH is poorly known, but recent works have suggested possible alterations of phototransduction. In this context, to identify biomarkers of IH, we studied the Post-Illumination Pupil Response (PIPR) using a specific pupillometry protocol reflecting the melanopsin-mediated pupil response in IH patients with prolonged total sleep time (TST > 660 min) and in healthy subjects. Twenty-eight patients with IH (women 86%, 25.4 year-old ± 4.9) and 29 controls (women 52%, 27.1 year-old ± 3.9) were included. After correction on baseline pupil diameter, the PIPR was compared between groups and correlated to sociodemographic and sleep parameters. We found that patients with IH had a lower relative PIPR compared to controls (32.6 ± 9.9% vs 38.5 ± 10.2%, p = 0.037) suggesting a reduced melanopsin response. In addition, the PIPR was not correlated to age, chronotype, TST, nor depressive symptoms. The melanopsin-specific PIPR may be an innovative trait marker of IH and the pupillometry might be a promising tool to better characterize hypersomnia.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 CNRS UPR 3212 & Strasbourg University, Institute for Cellular and Integrative Neurosciences, Strasbourg, France (GRID:grid.11843.3f) (ISNI:0000 0001 2157 9291)
2 CNRS UPR 3212 & Strasbourg University, Institute for Cellular and Integrative Neurosciences, Strasbourg, France (GRID:grid.11843.3f) (ISNI:0000 0001 2157 9291); Strasbourg University Hospital, CIRCSom (International Research Center for ChronoSomnology) & Sleep Disorders Center, Strasbourg, France (GRID:grid.412220.7) (ISNI:0000 0001 2177 138X)
3 Strasbourg University Hospital, CIRCSom (International Research Center for ChronoSomnology) & Sleep Disorders Center, Strasbourg, France (GRID:grid.412220.7) (ISNI:0000 0001 2177 138X)
4 CNRS UPR 3212 & Strasbourg University, Institute for Cellular and Integrative Neurosciences, Strasbourg, France (GRID:grid.11843.3f) (ISNI:0000 0001 2157 9291); Inovarion, Paris, France (GRID:grid.11843.3f)
5 CNRS UPR 3212 & Strasbourg University, Institute for Cellular and Integrative Neurosciences, Strasbourg, France (GRID:grid.11843.3f) (ISNI:0000 0001 2157 9291); Hôpital Bichat-Claude Bernard, Département de Psychiatrie et d’Addictologie, AP-HP, GHU Paris Nord, DMU Neurosciences, Paris, France (GRID:grid.411119.d) (ISNI:0000 0000 8588 831X); Université de Paris, NeuroDiderot, Inserm, FHU I2D2, Paris, France (GRID:grid.411119.d)